US20040131695A1 - Use of an aqueous solution in the treatment of live animals - Google Patents
Use of an aqueous solution in the treatment of live animals Download PDFInfo
- Publication number
- US20040131695A1 US20040131695A1 US10/679,449 US67944903A US2004131695A1 US 20040131695 A1 US20040131695 A1 US 20040131695A1 US 67944903 A US67944903 A US 67944903A US 2004131695 A1 US2004131695 A1 US 2004131695A1
- Authority
- US
- United States
- Prior art keywords
- aqueous
- solution
- animals
- oxidant
- anolyte
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 43
- 238000011282 treatment Methods 0.000 title claims abstract description 16
- 239000007864 aqueous solution Substances 0.000 title claims abstract description 13
- 244000000010 microbial pathogen Species 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 150000001450 anions Chemical class 0.000 claims abstract description 15
- 239000000243 solution Substances 0.000 claims description 67
- 238000000034 method Methods 0.000 claims description 31
- 239000003651 drinking water Substances 0.000 claims description 19
- 235000020188 drinking water Nutrition 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 17
- 241000282887 Suidae Species 0.000 claims description 12
- 230000001590 oxidative effect Effects 0.000 claims description 12
- 239000003963 antioxidant agent Substances 0.000 claims description 11
- 230000003078 antioxidant effect Effects 0.000 claims description 11
- 235000006708 antioxidants Nutrition 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 10
- 239000007800 oxidant agent Substances 0.000 claims description 10
- 244000144977 poultry Species 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 230000033116 oxidation-reduction process Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims description 2
- 238000005868 electrolysis reaction Methods 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 235000011151 potassium sulphates Nutrition 0.000 claims description 2
- 235000015424 sodium Nutrition 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 241000287828 Gallus gallus Species 0.000 description 13
- 229940079593 drug Drugs 0.000 description 13
- 244000005700 microbiome Species 0.000 description 10
- 235000013594 poultry meat Nutrition 0.000 description 7
- 235000013330 chicken meat Nutrition 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000000845 anti-microbial effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000021017 Weight Gain Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000005684 electric field Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 229930194936 Tylosin Natural products 0.000 description 2
- 239000004182 Tylosin Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 2
- 229960004059 tylosin Drugs 0.000 description 2
- 235000019375 tylosin Nutrition 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229910001905 dichlorine hexoxide Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000005838 radical anions Chemical class 0.000 description 1
- 150000005839 radical cations Chemical class 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to the use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals. More particularly, the invention relates to a remedy for improving the growth performance of pigs and poultry, and to a method of treating pigs and poultry to enhance their growth performance.
- the term “animal” should be construed to include within its meaning sheep, cattle, goats, pigs, chickens, ostriches, reptiles and the like; the term “disease” should be construed to include within its meaning diarrhoea; the term “pathogen” should be construed to include within its meaning microorganisms such as E-coli; and the term “medicament” should be construed to include within its meaning oral bactericides and bactericidal inhalants.
- the applicant envisages that the invention will be applicable particularly, but not exclusively, in the preparation of a medicament for use in the treatment of pathogenic microorganisms in weaner piglets and chicklets.
- the efficacy of a chosen control measure, or combination of measures is gauged in general by the percentage reduction in mortalities and the growth rate of survivors, taking into account the efficacy of growth (i.e. the amount of feed consumed per unit of growth). This is referred to as the feed conversion rate.
- a composition for treating live animals, and particularly pigs and poultry characterised therein that it treats pathogenic microorganisms, while at the same time enhancing growth performance in the animals
- the composition comprising an electrochemically activated aqueous solution including separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution, the electrochemically activated aqueous solution being characterised therein that it is produced by an electrochemical reactor including a through-flow, electrochemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between the electrodes so as to separate an annular inter-electrode space into a cathodic and an anodic chamber.
- a method of treating live animals, and in particular pigs and poultry, so as to treat pathogenic microorganisms, while at the same time enhancing growth performance in the animals comprising the steps of electrochemically activating an aqueous solution such that the solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution; separating the aqueous, mixed anti-oxidant, predominantly cation-containing solution from the aqueous, mixed oxidant, predominantly anion-containing solution; and introducing the aqueous, mixed anti-oxidant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution either simultaneously or sequentially into drinking water of the animal.
- the anion-containing solution is referred to hereinafter for brevity as the “anolyte solution” or “anolyte” and the cation-containing solution is referred to hereinafter for brevity as the “catholyte solution” or “catholyte”.
- the anolyte is introduced into the drinking water at between 5% and 20%, and preferably 15% by volume.
- the catholyte is used as the drinking water dosed at a rate equivalent to between 5 ml and 20 ml, and preferably an average of 10 ml per kilogram bodyweight of the animals to be treated.
- the applicant utilized a cylindrical electrolytic device, having at least one electrolytic cell, in which the anodic and cathodic chambers are separated by a permeable membrane and the specific design of which permits the harnessing of two distinct, separate and electrochemically different product streams of activated water, in a process known as electrolytic activation (EA) or electrochemical activation (ECA).
- EA electrolytic activation
- ECA electrochemical activation
- the design of the specific cell utilized by the applicant for this invention is such as to ensure a uniformly high voltage electrical field through which each micro-volume of water must pass.
- This electric field created in the cylindrical cell has a high potential gradient and results in the creation of solutions of which the pH, oxidation reduction potential (ORP) and other physico-chemical properties, lie outside of the range that can normally be achieved by conventional chemical or most electrolytic means.
- anolyte Two separate streams of activated solutions are produced, namely anolyte and catholyte.
- the anolyte typically can have a pH range of 1.5 to 9 and an oxidation-reduction potential (ORP) of +150 mV to +1200 mV.
- ORP oxidation-reduction potential
- the anolyte is oxidizing, due to the presence of a mixture of oxidizing free radical ions, and has an antimicrobial effect.
- the catholyte typically can have a pH range of 8.5 to 13 and an ORP of about ⁇ 150 mV to ⁇ 900 mV.
- the catholyte has reducing and surfactant properties and is an antioxidant.
- the anolyte should have a pH range of between 5.3 and 8.0 and an oxidation-reduction potential (ORP) in excess of +750 mV, while the catholyte should have a pH range of between 8.5 and 11 and an ORP of less than 600 mV.
- ORP oxidation-reduction potential
- the negatively charged anti-oxidant solution i.e. the catholyte
- the positively charged oxidant solution i.e. the anolyte that is produced.
- variations in the design of the hydraulic systems can be effected to meet the requisite objectives.
- the properties of electrolytically activated solutions are dependent upon a number of factors, including solution flow rate through the cell, type of salt used, voltage and current being applied, temperature, inter-flow dynamics of the solutions between the anode and cathode chambers, such as the degree of feedback of catholyte into the anolyte chamber, the design and geometry of the cell and the degree of mineralisation of the water.
- the anion-containing aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt.
- the salt may be sodium chloride.
- it may be non-iodated sodium or potassium chloride, carbonates, bicarbonate, sulphate or phosphate, electrolysed to produce radical cation and radical anion species. These species may be labile and after about 96 hours, the various radical species may disappear with no residues being produced.
- the anolyte solution may have a pH of between 5.3 and 7.5.
- the anolyte solution may include species such as ClO; ClO ⁇ ; HClO; OH ⁇ ; HO 2 ⁇ ; H 2 O 2 ; O 3 ; S 2 O 8 2 ⁇ and Cl 2 O 6 2 ⁇ . These species have been found to have a synergistic anti-bacterial and/or anti-viral effect, which is generally stronger than that of chemical bactericides and has been found to be particularly effective against viral organisms and spore and cyst forming bacteria.
- the redox potential of the anolyte solution may be monitored during the process so that the treatment process may be monitored and controlled on a continuous basis.
- the catholyte solution may include species such as NaOH; KOH; CA(OH) 2 ; Mg (OH) 2 ; HO ⁇ ; H 3 O 2 ⁇ ; HO 2 ⁇ ; H 2 O 2 ⁇ ; O 2 ⁇ ; OH ⁇ ;O 2 2 ⁇ .
- the method of treatment may include administering the anolyte solution by soaking, rinsing or dipping the animal in the anolyte solution, or applying the anolyte solution as an inhalant via an atomising or fogging process.
- the soaking, rinsing or dipping process is suitable for animals that can be handled with relative ease.
- the processes of atomising or fogging and oral administration by addition to drinking water are both suitable for animals such as weaner piglets and chicklets, which are susceptible to stress and accompanying weight loss.
- the atomising or fogging process may include the step of atomising the solution into the atmosphere in a volume to be treated, forming droplets of up to 100 micrometer.
- the method may include the preliminary step of enclosing the volume to be treated prior to atomising or fogging the enclosed volume.
- the atomising or fogging process is preferably conducted at pre-determined intervals so as to maintain a suitable level of anolyte concentration in the atmosphere, thus utilising the optimum microcidal and other properties of the anolyte solution in accordance with the required administration rate.
- the anolyte solution may also be applied by an atomising process in air ducting systems to destroy air-borne microorganisms and to destroy microorganisms present in the airways and lung tissue by inhalation.
- the treatment of the animal as described above may be conducted so as to improve the weight gain as a result of the anti-microbial action of the anolyte solution.
- the anolyte solution may have a specific anion concentration and distribution and a redox potential in accordance with the specific application.
- the pathogenic microorganisms to be treated may include enteric pathogenic microorganisms and respiratory pathogenic microorganisms.
- the basic electrolytic cells used to generate the electrolytically activated solutions utilized in this invention are modular units with the operational specifications for the reactors being optimised for each specific application.
- the cell includes a cylindrical metal vessel typically about 210 mm long and 16 mm in diameter, having a central rod anode (positive electrode) located within a concentric ceramic tube membrane.
- the outer tubular wall of the cell reactor acts as the cathode (negative electrode). Provision is made for inlet and outlet ports for the passage of the fluid through it.
- the ceramic membrane divides the cell into two compartments, the anode compartment and the cathode compartment. Water enters the cell and exits from these compartments as two streams, namely the anolyte and the catholyte, respectively. If so desired, some or all of the catholyte may be returned to the anode compartment so as to vary the properties of the anolyte being produced. Similarly, some or all of the anolyte may be returned to the cathode compartment so as to vary the properties of the catholyte being produced. A number of other hydraulic system configurations also exist, all of which are designed to achieve specific objectives.
- the design of the cell is such as to ensure a very high uniform electric field through which each micro volume of water must pass. In so doing the molecules of water in the anolyte and catholyte acquire special properties which cannot be reproduced by other (more conventional chemical) means.
- This electrolytic treatment results in the creation of anolyte and catholyte solutions whose pH, oxidation-reduction potentials (ORP) and other physico-chemical properties lie outside of the range that can be achieved by conventional chemical means.
- the anolyte solution was added to the drinking water of the weaner piglets over a period of 14 days and the results were measured in terms of average weight after the 14 day period.
- the average weight of the administered groups were compared with the average weight of the non-administered groups.
- the administered groups showed relative weight gain relative to the non-administered groups.
- the relative weight gains of the administered groups are reflected in Table 1 below.
- the efficacy of the use of the anolyte solution in the treatment of live animals depends upon the concentration of the anions in the anolyte solution, as measured by the oxidation-reduction potential (ORP) or redox potential of the anolyte solution, the flow rate through the reactor, the exposure time, i.e. the contact time between the contaminated animal and the anolyte solution and the temperature during application.
- ORP oxidation-reduction potential
- redox potential of the anolyte solution By measuring the redox potential of the anolyte solution during the treatment, for example, of a weaner piglet, the available free radical concentration can be monitored.
- Anolyte solution has been found to be more effective at lower than at higher temperatures.
- the applicant has found that growth rates in broiler chickens were significantly enhanced when the water source was treated with anolyte when compared to an untreated control group.
- the trial consisted of one control group and six treatment groups, each with three replicates of 50 chickens. All replicates were randomly assigned a trial enclosure within the same house, and all chickens were hatched on the same day from the same parent flock. Weight recordings were conducted every second week on the total group and on alternate weeks on individual chickens. All mortalities were recorded. Feed and water was supplied ad libitum and feed intake per replicate accurately recorded.
- Control group Received no medication in water Oxine water medication for 42 days Chemsol water medication for 42 days Anolyte (10%) water medication for 42 days Anolyte (15%) water medication for 12 days Anolyte (20%) water medication for 12 days
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention relates to a composition for use in the treatment of pathogenic microorganisms in a live animal, the composition comprising an electro-chemically activated, anion-containing aqueous solution.
Description
- This invention relates to the use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals. More particularly, the invention relates to a remedy for improving the growth performance of pigs and poultry, and to a method of treating pigs and poultry to enhance their growth performance.
- For the purposes of this specification, the term “animal” should be construed to include within its meaning sheep, cattle, goats, pigs, chickens, ostriches, reptiles and the like; the term “disease” should be construed to include within its meaning diarrhoea; the term “pathogen” should be construed to include within its meaning microorganisms such as E-coli; and the term “medicament” should be construed to include within its meaning oral bactericides and bactericidal inhalants. The applicant envisages that the invention will be applicable particularly, but not exclusively, in the preparation of a medicament for use in the treatment of pathogenic microorganisms in weaner piglets and chicklets.
- It will be appreciated that in the commercial rearing of domestic livestock, notably in the pig and poultry industries, the growth performance of animals forms the basis of economic viability of an operation. A number of factors may influence such growth performance such as temperature, diet, stocking rates, general husbandry and notably the presence and level of harmful pathogenic microorganisms. The microorganisms may be abundant in the water, food and in air space in which the animals are housed. In general, all pathogenic microorganisms exert a deleterious effect on the animal to a greater or lesser degree. This depends on factors such as the number of microorganisms present, the pathogenicity of the strain and its resistance to anti-microbials utilized in its control, as well as the immune status of an individual animal to a specific microorganism at any particular stage.
- Methods such as antimicrobial medication of feeding rations, water treatment and inoculations are commonly employed to reduce the severity of impact on the animal.
- The efficacy of a chosen control measure, or combination of measures, is gauged in general by the percentage reduction in mortalities and the growth rate of survivors, taking into account the efficacy of growth (i.e. the amount of feed consumed per unit of growth). This is referred to as the feed conversion rate.
- The current methods for the control of microorganisms is based on low level, and sometimes therapeutic, medication of feeding rations, as well as drinking water consumed by the animal. This practice has fallen out of favour in recent times due to the resistance being built up by microorganisms to antibiotics, as well as residue levels of such agents in meat consumed by people. The presence of antibiotic residues in food products leads to allergic and anaphylactic reactions in humans. The development of resistant strains of microorganisms makes anti-microbials ineffective. This method of disease control was recently banned in the European Union and other countries are following suit.
- It is accordingly an object of the invention to provide inexpensive, novel and alternative antimicrobials that overcome the above disadvantages.
- It is a further object of the present invention to provide a growth promoting remedy suitable for use in enhancing growth performance in animals, and in particular in pigs and poultry.
- It is another object of the invention to provide a method of treating animals, and in particular pigs and poultry, to promote their growth over any fixed period of time.
- It is a further object of the invention to disinfect contaminated water in animal production farms so that the water in effect becomes a disinfecting agent.
- According to a first aspect of the invention there is provided a composition for treating live animals, and particularly pigs and poultry, characterised therein that it treats pathogenic microorganisms, while at the same time enhancing growth performance in the animals, the composition comprising an electrochemically activated aqueous solution including separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution, the electrochemically activated aqueous solution being characterised therein that it is produced by an electrochemical reactor including a through-flow, electrochemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between the electrodes so as to separate an annular inter-electrode space into a cathodic and an anodic chamber.
- According to another aspect of the invention there is provided a method of treating live animals, and in particular pigs and poultry, so as to treat pathogenic microorganisms, while at the same time enhancing growth performance in the animals, the method comprising the steps of electrochemically activating an aqueous solution such that the solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution; separating the aqueous, mixed anti-oxidant, predominantly cation-containing solution from the aqueous, mixed oxidant, predominantly anion-containing solution; and introducing the aqueous, mixed anti-oxidant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution either simultaneously or sequentially into drinking water of the animal.
- The anion-containing solution is referred to hereinafter for brevity as the “anolyte solution” or “anolyte” and the cation-containing solution is referred to hereinafter for brevity as the “catholyte solution” or “catholyte”.
- The anolyte is introduced into the drinking water at between 5% and 20%, and preferably 15% by volume. The catholyte is used as the drinking water dosed at a rate equivalent to between 5 ml and 20 ml, and preferably an average of 10 ml per kilogram bodyweight of the animals to be treated.
- It is well known that animals are also infected via the oral route by the ingestion of infected litter, harbouring very high counts of pathogenic microorganisms. These particular pathogenic microorganisms enter the oral cavity and migrate towards the small intestine over a period of time. The applicant has found that introducing the predominantly anion-containing solution into the drinking water destroys these pathogenic microorganisms. Such a method prevents the microorganisms from migrating to the small intestine. The applicant refers this to as the “pre-pyloric” method of control as opposed to the traditional post-pyloric method utilized when medicating with antibiotics in food or drinking water.
- The applicant utilized a cylindrical electrolytic device, having at least one electrolytic cell, in which the anodic and cathodic chambers are separated by a permeable membrane and the specific design of which permits the harnessing of two distinct, separate and electrochemically different product streams of activated water, in a process known as electrolytic activation (EA) or electrochemical activation (ECA).
- The design of the specific cell utilized by the applicant for this invention is such as to ensure a uniformly high voltage electrical field through which each micro-volume of water must pass. This electric field created in the cylindrical cell has a high potential gradient and results in the creation of solutions of which the pH, oxidation reduction potential (ORP) and other physico-chemical properties, lie outside of the range that can normally be achieved by conventional chemical or most electrolytic means.
- Two separate streams of activated solutions are produced, namely anolyte and catholyte. Depending on the production methods used and conditions of operation of the device, the anolyte typically can have a pH range of 1.5 to 9 and an oxidation-reduction potential (ORP) of +150 mV to +1200 mV. The anolyte is oxidizing, due to the presence of a mixture of oxidizing free radical ions, and has an antimicrobial effect. The catholyte typically can have a pH range of 8.5 to 13 and an ORP of about −150 mV to −900 mV. The catholyte has reducing and surfactant properties and is an antioxidant. Through experimentation the applicant has found that for the treatment of live animals, the anolyte should have a pH range of between 5.3 and 8.0 and an oxidation-reduction potential (ORP) in excess of +750 mV, while the catholyte should have a pH range of between 8.5 and 11 and an ORP of less than 600 mV.
- One of the advantages of the design of the specific cell utilized by the authors for this invention is that the chemical composition of the two solutions can be altered by utilizing various hydraulic flow arrangements, linking electrolytic cell modules in various configurations in order optimally to address the requirements of specific areas of application. Some other variables are flow rate, hydraulic pressure, concentration, temperature, current density, and voltage on the electrodes.
- Aside from its distinctive attributes, the negatively charged anti-oxidant solution, i.e. the catholyte, can also be channeled back into the anode chamber, thereby modulating the quality of the positively charged oxidant solution, i.e. the anolyte that is produced. Depending on the specifications of the required application, variations in the design of the hydraulic systems can be effected to meet the requisite objectives.
- The properties of electrolytically activated solutions are dependent upon a number of factors, including solution flow rate through the cell, type of salt used, voltage and current being applied, temperature, inter-flow dynamics of the solutions between the anode and cathode chambers, such as the degree of feedback of catholyte into the anolyte chamber, the design and geometry of the cell and the degree of mineralisation of the water.
- It is important to note that the level of mineralisation of input water required to generate optimally formulated solutions is insignificantly different from the composition of potable water. However, the heightened electrical activity and altered physico-chemical attributes of the solutions differ significantly from the inactivated state, yet they remain non-toxic to animal tissue. Without maintenance of the activated state, these diverse products degrade to the relaxed state of benign water and the anomalous attributes of the activated solutions such as altered conductivity and surface tension similarly revert to pre-activation status.
- The applicant believes that increased growth performance is achieved because of a reduction or elimination of pathogenic microorganisms present in water, food and in the environment surrounding the animal. The applicant has found that water medication at levels of as low as 0.1% anolyte reduces the presence of pathogenic microorganisms contained in it, thus reducing the risk of the animal becoming infected by this route.
- The anion-containing aqueous solution may be prepared by means of electrolysis of an aqueous solution of a salt. The salt may be sodium chloride. In particular, it may be non-iodated sodium or potassium chloride, carbonates, bicarbonate, sulphate or phosphate, electrolysed to produce radical cation and radical anion species. These species may be labile and after about 96 hours, the various radical species may disappear with no residues being produced.
- The anolyte solution may have a pH of between 5.3 and 7.5. The anolyte solution may include species such as ClO; ClO −; HClO; OH−; HO2 −; H2O2; O3; S2O8 2−and Cl2O6 2−. These species have been found to have a synergistic anti-bacterial and/or anti-viral effect, which is generally stronger than that of chemical bactericides and has been found to be particularly effective against viral organisms and spore and cyst forming bacteria. The redox potential of the anolyte solution may be monitored during the process so that the treatment process may be monitored and controlled on a continuous basis.
- The catholyte solution may include species such as NaOH; KOH; CA(OH) 2; Mg (OH)2; HO−; H3O2 −; HO2 −; H2O2 −; O2 −; OH−;O2 2−.
- The method of treatment may include administering the anolyte solution by soaking, rinsing or dipping the animal in the anolyte solution, or applying the anolyte solution as an inhalant via an atomising or fogging process. The soaking, rinsing or dipping process is suitable for animals that can be handled with relative ease.
- The processes of atomising or fogging and oral administration by addition to drinking water are both suitable for animals such as weaner piglets and chicklets, which are susceptible to stress and accompanying weight loss. The atomising or fogging process may include the step of atomising the solution into the atmosphere in a volume to be treated, forming droplets of up to 100 micrometer. The method may include the preliminary step of enclosing the volume to be treated prior to atomising or fogging the enclosed volume.
- The atomising or fogging process is preferably conducted at pre-determined intervals so as to maintain a suitable level of anolyte concentration in the atmosphere, thus utilising the optimum microcidal and other properties of the anolyte solution in accordance with the required administration rate.
- The anolyte solution may also be applied by an atomising process in air ducting systems to destroy air-borne microorganisms and to destroy microorganisms present in the airways and lung tissue by inhalation.
- The treatment of the animal as described above may be conducted so as to improve the weight gain as a result of the anti-microbial action of the anolyte solution.
- The anolyte solution may have a specific anion concentration and distribution and a redox potential in accordance with the specific application.
- The pathogenic microorganisms to be treated may include enteric pathogenic microorganisms and respiratory pathogenic microorganisms.
- A preferred embodiment of the invention will now be described with reference to the accompanying experiments.
- In a series of experiments, the bactericidal effect of the anolyte solution was tested on animals. The results are reflected in the tables below.
- The basic electrolytic cells used to generate the electrolytically activated solutions utilized in this invention are modular units with the operational specifications for the reactors being optimised for each specific application. The cell includes a cylindrical metal vessel typically about 210 mm long and 16 mm in diameter, having a central rod anode (positive electrode) located within a concentric ceramic tube membrane. The outer tubular wall of the cell reactor acts as the cathode (negative electrode). Provision is made for inlet and outlet ports for the passage of the fluid through it.
- Effectively, the ceramic membrane divides the cell into two compartments, the anode compartment and the cathode compartment. Water enters the cell and exits from these compartments as two streams, namely the anolyte and the catholyte, respectively. If so desired, some or all of the catholyte may be returned to the anode compartment so as to vary the properties of the anolyte being produced. Similarly, some or all of the anolyte may be returned to the cathode compartment so as to vary the properties of the catholyte being produced. A number of other hydraulic system configurations also exist, all of which are designed to achieve specific objectives.
- The design of the cell is such as to ensure a very high uniform electric field through which each micro volume of water must pass. In so doing the molecules of water in the anolyte and catholyte acquire special properties which cannot be reproduced by other (more conventional chemical) means. This electrolytic treatment results in the creation of anolyte and catholyte solutions whose pH, oxidation-reduction potentials (ORP) and other physico-chemical properties lie outside of the range that can be achieved by conventional chemical means.
- In this invention the pH, ORP and concentration values of chlorine, chlorides and other dissolved salts have been determined, unless otherwise stated, as per standard methods of examination of water and effluents.
- Experiment 1—Weaner Piglets
- The anolyte solution was added to the drinking water of the weaner piglets over a period of 14 days and the results were measured in terms of average weight after the 14 day period. The average weight of the administered groups were compared with the average weight of the non-administered groups.
- The administered groups showed relative weight gain relative to the non-administered groups. The relative weight gains of the administered groups are reflected in Table 1 below.
- Experiment 2—Broilers (Chicklets)
- Day old broilers were administered with anolyte solution (10% diluted) by addition to drinking water for 7 days. (Group C3-12 000 chicklets). No antibiotic medication was administered during that time. Untreated control groups (C1, C2, C4 and C5=total 48 000 chicklets) received normal drinking water during that time. The untreated groups were routinely medicated with Tylosin for 3 consecutive days.
- Bacterial analyses of the drinking water of all groups were regularly conducted during the first 7 days. Other measurements included daily mortalities and morbidities throughout and pH and ORP determinations of the drinking water during the first 7 days. All results are reflected in Table 2 below.
- Medication of drinking water with anolyte solution supplied to day-old chicklets for the first period resulted in a significant reduction in mortalities throughout the growth and finishing period. Mortalities increased in all the groups from the 4th week onwards mainly due to respiratory disease. It is envisaged that these could be reduced by fogging the environment with anolyte solution to eliminate airborne respiratory pathogens by means of respiratory intake.
- It has been found that the efficacy of the use of the anolyte solution in the treatment of live animals depends upon the concentration of the anions in the anolyte solution, as measured by the oxidation-reduction potential (ORP) or redox potential of the anolyte solution, the flow rate through the reactor, the exposure time, i.e. the contact time between the contaminated animal and the anolyte solution and the temperature during application. By measuring the redox potential of the anolyte solution during the treatment, for example, of a weaner piglet, the available free radical concentration can be monitored. Anolyte solution has been found to be more effective at lower than at higher temperatures.
- The applicant has found that growth rates in broiler chickens were significantly enhanced when the water source was treated with anolyte when compared to an untreated control group. The trial consisted of one control group and six treatment groups, each with three replicates of 50 chickens. All replicates were randomly assigned a trial enclosure within the same house, and all chickens were hatched on the same day from the same parent flock. Weight recordings were conducted every second week on the total group and on alternate weeks on individual chickens. All mortalities were recorded. Feed and water was supplied ad libitum and feed intake per replicate accurately recorded. The following treatments were applied:
Control group Received no medication in water Oxine water medication for 42 days Chemsol water medication for 42 days Anolyte (10%) water medication for 42 days Anolyte (15%) water medication for 12 days Anolyte (20%) water medication for 12 days - Chickens were slaughtered at 42 days, at which time final live weights and food intake over the period recorded.
- The following table summarizes the results (i.e. weight in grams):
MEDICATION DAY 0 DAY 7 DAY 14 DAY 21 DAY 28 DAY 35 DAY 42 Control 39.0 90.6 129.7 441.2 795.2 1284.7 1903.4 Oxine 39.3 94.7 200.3 461.7 815.5 1346.2 1955.9 Chematron 40.7 118.0 259.2 571.0 960.0 1495.2 2119.0 10% Anolyte 40.0 126.9 278.0 603.4 1031.8 1592.6 2227.8 15% Anolyte 40.0 130.7 294.8 631.3 1061.6 1650.7 2283.3 20% Anolyte 40.0 125.3 283.7 579.9 1006.0 1572.3 2106.8 - Production parameters (as measured by mortality reduction, final slaughter mass, kilogram meat produced per m 2 floor space and feed conversion rates) in the following example were significantly enhanced. In this trial the above parameters obtained on the same site in 2 previous cycles (i.e. 110 and 111) were compared to the experimental one (i.e. 112) where broiler chickens were again treated with anolyte. The site consisted of 6 broiler houses each stocked with 27 00 broilers.
FEED CYCLE AVE FLOCK MORTALITY AVE AVE MASS KG/M2 CONVERSION NO AGE % AGE (KG) PER HOUSE RATE 110 37.1 6.01 39.5 1.805 30.97 1.88 111 37.1 9.09 39.0 1.741 29.23 1.92 112 36.6 5.25 40.9 2.006 35.07 1.86 - It is evident from the above results that when the anionic solution was dosed into the drinking water at an inclusion rate of 15%, fewer chickens died, the live mass was significantly higher whilst converting food more efficiently. In this trial approximately 5 kg live mass per square meter floor space, equating to 7.35 tonnes per house or 44.1 tonnes per site additional meat, was produced. No antibiotic water medication was employed in cycle 112 whilst in both preceding cycles FOSBAC (fosamycin 20% and tylosin 5%) was used.
- In this trial the effect of the addition of anolyte on the productivity of weaners was studied. The trial was carried out over two rounds with a total of 16 replicates per round and 400 pigs per group. Microbial examinations of drinking water showed the total number of bacteria to be reduced from 3 500 000/ml to zero and of Coliforms from >160/ml to zero when either 25% or 10% anolyte was added. Mortalities and clinical cases showed no difference between treatment and control groups.
- The following table summarizes results:
GROUP CONTROL ANOLYTE Number of pens 16 16 Number of pigs penned 408 408 Daily gain (g) - first 2 116 141 weeks post weaning Daily feed intake - first 0.22 0.24 2 weeks post weaning (kg) Feed conversion 1.94 1.72 (kg feed/kg gain) - It will be appreciated that many variations in detail are possible without departing from the scope and/or spirit of the invention as set out in the claims hereinafter.
Claims (12)
1. A composition for treating live animals, and particularly pigs and poultry, characterised therein that it treats pathogenic microorganisms, while at the same time enhancing growth performance in the animals, the composition comprising an electrochemically activated aqueous solution including separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution, the composition further being characterised therein that it is produced through electrolysis of an aqueous solution of a salt, particularly sodium or potassium chloride, carbonates, bicarbonates, sulphates or phosphates.
2. A method of treating live animals, and in particular pigs and poultry, so as treat pathogenic microorganisms, while at the same time enhancing growth performance in the animals, the method comprising the steps of electrochemically activating an aqueous solution such that the solution includes separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution; separating the aqueous, mixed anti-oxidant, predominantly cation-containing solution from the aqueous, mixed oxidant, predominantly anion-containing solution; and introducing the aqueous, mixed anti-oxidant, predominantly cation-containing solution and the aqueous, mixed oxidant, predominantly anion-containing solution either simultaneously or sequentially into drinking water of the animals.
3. The method as claimed in claim 2 characterised therein that the anolyte is introduced into the drinking water of the animals at between 5% and 20%, and preferably 15% by volume.
4. The method as claimed in claim 2 characterised therein that the catholyte is used as the drinking water and dosed at a rate equivalent to between 5 ml and 20 ml, and preferably an average of 10 ml per kilogram bodyweight of the animals to be treated.
5. The composition as claimed in claim 1 characterised therein that the anolyte has a pH range of between 5.3 and 8.0 and an oxidation-reduction potential (ORP) in excess of +750 mV, while the catholyte has a pH range of between 8.5 and 11 and an ORP of less than −600 mV.
6. The composition as claimed in claim 1 characterised therein that the chemical composition of the two solutions can be altered by utilizing various hydraulic flow arrangements, linking electrolytic cell modules in various configurations in order optimally to address the requirements of specific areas of application, as well as through manipulation of flow rate, hydraulic pressure, concentration, temperature, current density and voltage on the electrodes.
7. The method as claimed in claim 6 characterised therein that the negatively charged catholyte can be channelled back into the anode chamber so as to modulate the quality of the positively charged anolyte being produced, whilst the positively charged anolyte can be channelled back into the cathodic chamber so as to modulate the quality of the negatively charged catholyte being produced.
8. The method as claimed in claim 2 characterised therein that additional steps of administering the solution are by soaking, rinsing or dipping the animal in the solution; or applying the solution as an inhalant as an aerosol via an atomising or fogging process.
9. The method as claimed in claim 9 characterised therein that the atomising or fogging process includes the step of atomising the solution into the atmosphere in a volume to be treated, forming droplets of up to 100 micrometer.
10. Use of a composition in the preparation of a medicament for use in the treatment of live animals, and particularly pigs and poultry, for treating pathogenic microorganisms, while at the same time enhancing growth performance in the animals, the composition comprising an electrochemically activated aqueous solution including separable and both of an aqueous, mixed oxidant, predominantly anion-containing solution and an aqueous, mixed anti-oxidant, predominantly cation-containing solution, the electrochemically activated aqueous solution being characterised therein that it is produced by an electrochemical reactor including a through-flow, electrochemical cell having two co-axial cylindrical electrodes with a co-axial diaphragm between the electrodes so as to separate an annular inter-electrode space into a cathodic and an anodic chamber.
11. A composition for treating live animals substantially as herein illustrated with reference to the accompanying examples.
12. A method of treating live animals substantially as herein illustrated with reference to the accompanying examples.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/679,449 US20040131695A1 (en) | 1997-10-23 | 2003-10-07 | Use of an aqueous solution in the treatment of live animals |
| US11/652,199 US7651704B2 (en) | 1997-10-23 | 2007-01-11 | Use of an aqueous solution in the treatment of live animals |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA97/9486 | 1997-10-23 | ||
| ZA979486 | 1997-10-23 | ||
| US52973400A | 2000-06-19 | 2000-06-19 | |
| US10/679,449 US20040131695A1 (en) | 1997-10-23 | 2003-10-07 | Use of an aqueous solution in the treatment of live animals |
Related Parent Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/022372 Continuation-In-Part WO1999020287A1 (en) | 1997-10-23 | 1998-10-23 | The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals |
| US09529734 Continuation-In-Part | 1998-10-23 | ||
| US52973400A Continuation-In-Part | 1997-10-23 | 2000-06-19 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/652,199 Continuation US7651704B2 (en) | 1997-10-23 | 2007-01-11 | Use of an aqueous solution in the treatment of live animals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20040131695A1 true US20040131695A1 (en) | 2004-07-08 |
Family
ID=38041125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/679,449 Abandoned US20040131695A1 (en) | 1997-10-23 | 2003-10-07 | Use of an aqueous solution in the treatment of live animals |
| US11/652,199 Expired - Lifetime US7651704B2 (en) | 1997-10-23 | 2007-01-11 | Use of an aqueous solution in the treatment of live animals |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US11/652,199 Expired - Lifetime US7651704B2 (en) | 1997-10-23 | 2007-01-11 | Use of an aqueous solution in the treatment of live animals |
Country Status (1)
| Country | Link |
|---|---|
| US (2) | US20040131695A1 (en) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7090753B2 (en) | 2001-09-14 | 2006-08-15 | Oculus Innovative Sciences, Inc. | Electrolytic cell for producing charged anode water suitable for surface cleaning or treatment, and method for producing the same and use of the same |
| WO2010011927A1 (en) * | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US20110030959A1 (en) * | 2007-01-12 | 2011-02-10 | Emmons Stuart A | Aqueous Solution For Managing Microbes In Oil And Gas Production And Method For Their Production |
| US8062500B2 (en) | 2001-12-05 | 2011-11-22 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (ORP) water |
| US8147444B2 (en) | 2006-01-20 | 2012-04-03 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US8323252B2 (en) | 2005-03-23 | 2012-12-04 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| US20140287065A1 (en) * | 2013-03-14 | 2014-09-25 | Ag Odor Control, LLC | Oral Administration of Electrolyzed Water for Treatment and Prevention of PEDv in Swine, Swine Herds and Swine Confinements |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| EP2632857A4 (en) * | 2010-10-28 | 2016-01-13 | Anolytech Ab | Process and system for producing an anolyte fraction |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| US9572810B2 (en) | 2010-07-22 | 2017-02-21 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014526520A (en) | 2011-09-16 | 2014-10-06 | ズレックス ファーマグラ,エルエルシー | Sterilization composition production system and method |
| US20150104525A1 (en) * | 2013-10-10 | 2015-04-16 | Reoxcyn Discoveries Group, Inc. | Method of decreasing feed conversion ratio in fowl |
| US11213286B2 (en) * | 2020-04-06 | 2022-01-04 | Simple Innovative Solutions, LLC | Self-retaining retractor |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5540819A (en) * | 1992-06-04 | 1996-07-30 | Nauchno-Proizvodstvennoe Obiedinenie "Ekran" Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Water treatment method |
| US5628888A (en) * | 1996-03-28 | 1997-05-13 | Rscecat, Usa, Inc. | Apparatus for electrochemical treatment of water and/or water solutions |
| US5635040A (en) * | 1996-03-11 | 1997-06-03 | Rscecat, Usa, Inc. | Electrochemical cell |
| US5674537A (en) * | 1990-05-23 | 1997-10-07 | Medical Discoveries, Inc. | Electrolyzed saline solution containing concentrated amounts of ozone and chlorine species |
| US5985110A (en) * | 1996-03-28 | 1999-11-16 | Bakhir; Vitold M. | Apparatus for electrochemical treatment of water and/or water solutions |
| US6871623B2 (en) * | 2001-10-19 | 2005-03-29 | Kioritz Corp. | Working machine having a single operation unit |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3616355A (en) | 1968-08-05 | 1971-10-26 | Kdi Chloro Guard Corp | Method of generating enhanced biocidal activity in the electroylsis of chlorine containing solutions and the resulting solutions |
| WO1993020014A1 (en) | 1992-04-03 | 1993-10-14 | Bakhir Vitold M | Device for electrochemical processing of water |
| BR9201704A (en) | 1992-04-28 | 1993-11-03 | Takeshi Imai | SPRAYING PROCESS OF Aqueous HYPOCLORITE SOLUTIONS FOR THE CONTROL OF CHOLEERIDIC EPIDEMICS |
| JPH07328628A (en) | 1994-06-15 | 1995-12-19 | Kyushu Hitachi Maxell Ltd | Electrolytic water conditioner |
| US5871623A (en) | 1995-05-31 | 1999-02-16 | Rscecat, Usa, Inc. | Apparatus for electrochemical treatment of water and/or water solutions |
| WO1999020287A1 (en) | 1997-10-23 | 1999-04-29 | Radical Waters Ip (Pty) Ltd | The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals |
| US20040081705A1 (en) * | 2002-09-18 | 2004-04-29 | Mana Gotou | Digestion promoter for ruminant animal and breeding method of ruminant animal |
-
2003
- 2003-10-07 US US10/679,449 patent/US20040131695A1/en not_active Abandoned
-
2007
- 2007-01-11 US US11/652,199 patent/US7651704B2/en not_active Expired - Lifetime
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674537A (en) * | 1990-05-23 | 1997-10-07 | Medical Discoveries, Inc. | Electrolyzed saline solution containing concentrated amounts of ozone and chlorine species |
| US5540819A (en) * | 1992-06-04 | 1996-07-30 | Nauchno-Proizvodstvennoe Obiedinenie "Ekran" Vsesojuzny Nauchno-Issledovatelsky I Ispytatelny Institut Meditsinskoi Tekhniki | Water treatment method |
| US5635040A (en) * | 1996-03-11 | 1997-06-03 | Rscecat, Usa, Inc. | Electrochemical cell |
| US5628888A (en) * | 1996-03-28 | 1997-05-13 | Rscecat, Usa, Inc. | Apparatus for electrochemical treatment of water and/or water solutions |
| US5985110A (en) * | 1996-03-28 | 1999-11-16 | Bakhir; Vitold M. | Apparatus for electrochemical treatment of water and/or water solutions |
| US6871623B2 (en) * | 2001-10-19 | 2005-03-29 | Kioritz Corp. | Working machine having a single operation unit |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442288B2 (en) | 2001-09-14 | 2008-10-28 | Oculus Innovative Sciences, Inc. | Electrolytic cell for producing charged anode water suitable for surface cleaning or treatment, and method for producing the same and use of the same |
| US7090753B2 (en) | 2001-09-14 | 2006-08-15 | Oculus Innovative Sciences, Inc. | Electrolytic cell for producing charged anode water suitable for surface cleaning or treatment, and method for producing the same and use of the same |
| US8062500B2 (en) | 2001-12-05 | 2011-11-22 | Oculus Innovative Sciences, Inc. | Method and apparatus for producing negative and positive oxidative reductive potential (ORP) water |
| US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
| US10016455B2 (en) | 2003-12-30 | 2018-07-10 | Sonoma Pharmaceuticals, Inc. | Method of preventing or treating influenza with oxidative reductive potential water solution |
| US9642876B2 (en) | 2003-12-30 | 2017-05-09 | Sonoma Pharmaceuticals, Inc. | Method of preventing or treating sinusitis with oxidative reductive potential water solution |
| US8323252B2 (en) | 2005-03-23 | 2012-12-04 | Oculus Innovative Sciences, Inc. | Method of treating skin ulcers using oxidative reductive potential water solution |
| US8840873B2 (en) | 2005-03-23 | 2014-09-23 | Oculus Innovative Sciences, Inc. | Method of treating second and third degree burns using oxidative reductive potential water solution |
| US9498548B2 (en) | 2005-05-02 | 2016-11-22 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
| US9782434B2 (en) | 2006-01-20 | 2017-10-10 | Sonoma Pharmaceuticals, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US9072726B2 (en) | 2006-01-20 | 2015-07-07 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution |
| US8834445B2 (en) | 2006-01-20 | 2014-09-16 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US8147444B2 (en) | 2006-01-20 | 2012-04-03 | Oculus Innovative Sciences, Inc. | Methods of treating or preventing peritonitis with oxidative reductive potential water solution |
| US20110030959A1 (en) * | 2007-01-12 | 2011-02-10 | Emmons Stuart A | Aqueous Solution For Managing Microbes In Oil And Gas Production And Method For Their Production |
| US9089511B2 (en) | 2008-07-25 | 2015-07-28 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9089602B2 (en) | 2008-07-25 | 2015-07-28 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US9775798B2 (en) | 2008-07-25 | 2017-10-03 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| WO2010011927A1 (en) * | 2008-07-25 | 2010-01-28 | Noventis, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US11110053B2 (en) | 2008-07-25 | 2021-09-07 | Reven Pharmaceuticals Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| US10342825B2 (en) | 2009-06-15 | 2019-07-09 | Sonoma Pharmaceuticals, Inc. | Solution containing hypochlorous acid and methods of using same |
| US9572810B2 (en) | 2010-07-22 | 2017-02-21 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| US9867849B2 (en) | 2010-07-22 | 2018-01-16 | Reven Pharmaceuticals, Inc. | Methods of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| US11202798B2 (en) | 2010-07-22 | 2021-12-21 | Reven Pharmaceuticals, Inc. | Method of treating or ameliorating skin conditions with a magnetic dipole stabilized solution |
| EP2632857A4 (en) * | 2010-10-28 | 2016-01-13 | Anolytech Ab | Process and system for producing an anolyte fraction |
| US9283250B2 (en) * | 2013-03-14 | 2016-03-15 | Ag Odor Control, LLC | Oral administration of electrolyzed water for treatment and prevention of PEDv in swine, swine herds and swine confinements |
| US20140287065A1 (en) * | 2013-03-14 | 2014-09-25 | Ag Odor Control, LLC | Oral Administration of Electrolyzed Water for Treatment and Prevention of PEDv in Swine, Swine Herds and Swine Confinements |
Also Published As
| Publication number | Publication date |
|---|---|
| US20070110822A1 (en) | 2007-05-17 |
| US7651704B2 (en) | 2010-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7651704B2 (en) | Use of an aqueous solution in the treatment of live animals | |
| US20020175085A1 (en) | Method for sanitizing shells of eggs using electrolyzed oxidizing water | |
| US5830511A (en) | Therapeutic, production and immunostimulatory uses of biocidal compositions | |
| CN101076322A (en) | Antimicrobial composition for pre-harvest and post-harvest treatment of plants and animals | |
| JP5216087B2 (en) | Membrane electrolysis and use of the products obtained thereby | |
| CN102228058A (en) | Citric acid composite disinfectant | |
| CN103249680B (en) | Method and system for producing an anolyte fraction | |
| US6099855A (en) | Therapeutic, production and immunostimulatory uses of biocidal compositions | |
| CN115886029A (en) | Low-temperature hypochlorous acid disinfectant, and preparation method and application thereof | |
| EP1047435A1 (en) | The use of an aqueous solution in the preparation of a medicament for use in the treatment of live animals | |
| Chechet et al. | Study the effectiveness of using a complex of disinfectants and probiotics in the presence of poultry | |
| US6004587A (en) | Therapeutic, production and immunostimulatory uses of biocidal compositions | |
| CN202637549U (en) | Ionized water spray disinfection and sterilization device for forest frog breeding shed | |
| Williams | Formalin destruction of salmonellae in poultry litter | |
| CN101795570B (en) | Aqueous composition for inactivating sporulated and/or non-sporulated coccidian parasites | |
| RU2054291C1 (en) | Method of prophylaxis and treatment of bronchial pneumonia and dyspepsia in agriculture animal and poultry | |
| RU2156060C1 (en) | Bee servicing method | |
| KR102461469B1 (en) | Drinking water composition for hypochlorous acid livestock | |
| JP4052535B2 (en) | Animal drugs and animal feed | |
| Singh et al. | Egg safety in the realm of preharvest food safety | |
| Karomy et al. | Effect of the frequency of the microsafe spraying on the production performance and the microbial presence in mouth and vent of broiler chickens | |
| CN100361584C (en) | Broad-spectrum antiseptics and production thereof | |
| IE20160180A1 (en) | A composition and a method for controlling bacterial infection | |
| JP4602005B2 (en) | Antibacterial and deodorant for livestock and poultry | |
| RU2570739C1 (en) | Method of thermochemical disinfection of livestock premises in liquidation of african swine fever |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: RADICAL WATERS IP (PTY) LTD., SOUTH AFRICA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HINZE, GILBERT THEO;REEL/FRAME:018101/0094 Effective date: 20060811 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |